{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T22:01:01Z","timestamp":1778623261528,"version":"3.51.4"},"reference-count":11,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2007,3,1]],"date-time":"2007-03-01T00:00:00Z","timestamp":1172707200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,3,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Transdermal and intralesional verapamil has been reported to be useful in the treatment of Peyronie\u2019s Disease. This study evaluates a topically applied calcium channel blocker (verapamil hydrochloride 15% gel), a topically applied calmodulin blocker (trifluoperazine), and a topically applied weak calcium channel blocker (magnesium sulfate), each incorporated in a transdermal vehicle.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Aim<\/jats:title>\n                  <jats:p>This pilot study was conducted to assess the efficacy of a 15% verapamil gel applied topically to the penile shaft twice daily for the treatment of Peyronie\u2019s Disease.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Main Outcome Measure<\/jats:title>\n                  <jats:p>To assess improvement in curvature, plaque size, resolution of painful erections, and improvement in erection quality.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Two simultaneous, three armed, double blinded, placebo-controlled studies were conducted. After randomization into one of four groups, patients were treated for 3 months. At the end of 3 months\u2019 treatment using blinded drug, each patient was treated with open label topical verapamil for 6 months. The studies were completed after each patient had been treated and evaluated for 9 months after randomization.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Fifty-seven patients were randomized. In total, 94.4% of patients treated for 9 months with topical verapamil experienced improvement in curvature with an average percent curvature change of 61.1% compared with 43.6% curvature improvement at 3 months. At 9 months the average percent plaque change was 84.7% compared with 55% at 3 months. Pain resolution at 9 months was 100% compared with 87.5% at 3 months. Patient perception of erection quality also increased at 9 months to 81.8% compared with 72.7% at 3 months.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Topical verapamil gel proved effective in eliminating pain on erection, decreasing the size of plaque, decreasing curvature, and improving erection quality in patients with Peyronie\u2019s Disease. Treatment results improved significantly after 9 months\u2019 treatment as compared with 3 months\u2019 treatment.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1111\/j.1743-6109.2006.00417.x","type":"journal-article","created":{"date-parts":[[2007,3,13]],"date-time":"2007-03-13T11:23:30Z","timestamp":1173785010000},"page":"477-484","source":"Crossref","is-referenced-by-count":68,"title":["Topical Verapamil HCl, Topical Trifluoperazine, and Topical Magnesium Sulfate for the Treatment of Peyronie\u2019s Disease\u2014 A Placebo-Controlled Pilot Study"],"prefix":"10.1093","volume":"4","author":[{"suffix":"III,","given":"William P.","family":"Fitch,","sequence":"first","affiliation":[{"name":"Urology Consultants, P.A. , San Antonio , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W. Jerry","family":"Easterling","sequence":"additional","affiliation":[{"name":"PDL , San Antonio , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert L.","family":"Talbert","sequence":"additional","affiliation":[{"name":"University of Texas Health Science Center at San Antonio , San Antonio , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Bordovsky","sequence":"additional","affiliation":[{"name":"Private Consultant , San Antonio , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Mosier","sequence":"additional","affiliation":[{"name":"Washburn University , Topeka , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2007,3,1]]},"reference":[{"key":"2024032600453113500_bib1","first-page":"425","article-title":"de la: Sur quelques obstacles qui s\u2019opposerta l\u2019ejaculation naturelle de la semence. Mem\u2019l Acad","volume":"I","author":"Peyronie","year":"1743","journal-title":"Roy de Chir"},{"key":"2024032600453113500_bib2","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/S0022-5347(17)37988-0","article-title":"The incidence of Peyronie\u2019s Disease in Rochester, Minnesota, 1950 through 1984","volume":"146","author":"Lindsay","year":"1991","journal-title":"J Urol"},{"key":"2024032600453113500_bib3","first-page":"167","article-title":"Prevalence or Peyronie\u2019s Disease: Results of an 8,000 man survey","volume":"163","author":"Schwarzer","year":"2000","journal-title":"J Urol Suppl"},{"key":"2024032600453113500_bib4","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/sj.ijir.3900727","article-title":"Prevalence of Peyronie\u2019s Disease in men over 50-y-old from Southern Brazil","volume":"13","author":"Rhoden","year":"2001","journal-title":"Int J Impot Res"},{"key":"2024032600453113500_bib5","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1083\/jcb.98.5.1662","article-title":"Changes in cell shape correlate with collagenase gene expression in rabbit synovial fibroblasts","volume":"98","author":"Aggeler","year":"1984","journal-title":"J Cell Biol"},{"key":"2024032600453113500_bib6","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1126\/science.2994224","article-title":"Pathways of protein secretion in Eukaryotes","volume":"230","author":"Kelly","year":"1985","journal-title":"Science"},{"key":"2024032600453113500_bib7","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S0022-5347(05)64691-5","article-title":"Greenfield: Experience with intraplaque injection of verapamil for Peyronie\u2019s Disease","volume":"168","author":"Laurence","year":"2002","journal-title":"J Urol"},{"key":"2024032600453113500_bib8","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/0022-4804(90)90197-A","article-title":"Calcium antagoniss retard extracellular matrix production in connective tissue equivalent","volume":"49","author":"Lee","year":"1990","journal-title":"J Surg Res"},{"key":"2024032600453113500_bib9","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1016\/S0022-5347(05)64173-0","article-title":"Transdermal application of verapamil gel to the penile shaft fails to infiltrate the tunica albuginea","volume":"168","author":"Martin","year":"2002","journal-title":"J Urol"},{"key":"2024032600453113500_bib10","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1002\/j.1552-4604.1997.tb04331.x","article-title":"Postabsorption concentration peaks with brand-name and generic verapamil: A double blind, cross-over study in elderly hypertensive patients","volume":"37","author":"Saseen","year":"1997","journal-title":"J Clin Pharmacol"},{"key":"2024032600453113500_bib11","first-page":"978","article-title":"Molecular biology of the cell","author":"Alberts","year":"1994","edition":"3rd edition"}],"container-title":["The Journal of Sexual Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1743609515315290?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1743609515315290?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/4\/2\/477\/47809581\/jsm_4_2_477.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/4\/2\/477\/47809581\/jsm_4_2_477.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T01:36:32Z","timestamp":1711416992000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jsm\/article\/4\/2\/477\/6889810"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,3,1]]},"references-count":11,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2007,3,1]]},"published-print":{"date-parts":[[2007,3,1]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1743-6109.2006.00417.x","relation":{},"ISSN":["1743-6109","1743-6095"],"issn-type":[{"value":"1743-6109","type":"electronic"},{"value":"1743-6095","type":"print"}],"subject":[],"published-other":{"date-parts":[[2007,3]]},"published":{"date-parts":[[2007,3,1]]}}}